Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Dupilumab is a monoclonal antibody that inhibits IL-4 and IL-13 signaling by targeting the IL-4 receptor a-subunit and is currently approved for treatment of atopic dermatitis (AD), asthma, and nasal polyposis. Currently, a single case report describes tolerance to foods which previously caused anaphylaxis after starting dupilumab treatment. However, to our knowledge the effect of dupilumab on serologic markers of FA has not been described.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
